

# Tonix Pharmaceuticals

16:00 24 Jan 2020

## NA Proactive news snapshot: PowerOre, Black Iron, Helix Technologies, The Valens Company UPDATE

...

PowerOre Inc (CVE:PORE) has closed its final tranche and hard dollar portion of its non-brokered private placement which generated aggregate proceeds of \$150,000. Upon closing of the offering, the company issued 3 million units at a price of \$0.05 per Hard Dollar Unit, where each Hard Dollar Unit consists of one common share and one-half of one common share purchase warrant. Each whole warrant will entitle the holder to purchase one additional common share of the company at a price of \$0.07 for a period of 24 months from the date of issuance.

Black Iron Inc (TSE:BKI) (OTCMKTS:BKIRF) CEO Matt Simpson brought the Shymanivske story to world leaders and investors at the World Economic Forum in Davos, Switzerland last week. Simpson participated in a panel discussion at the Ukraine House event during the forum to talk about the firm's experience as a major investor in Ukraine. The Toronto-based firm is advancing the Shymanivske iron ore project in the country, a 646-million-ton resource that is primed for construction.

Helix Technologies Inc (OTCMKTS:HLIX) is signed on to be a featured presenter at the upcoming MjMicro Virtual Investor Conference on January 29. The conference, hosted by MjInvest, is run by MjLink.com Inc, a subsidiary of Social Life Network (OTCMKTD:WLDF). Helix President of Data Services Garvis Toler will give a presentation updating investors and analysts on the state of the company, which provides comprehensive supply chain management, compliance tools, and asset protection to the cannabis industry. The presentation will be livestreamed at 11 am PT (2 pm ET) here.

Canaccord Genuity has initiated coverage of The Valens Company (CVE:VLNS) (OCTMKTS:VLNCF) with a Speculative Buy recommendation and a \$8 price target. "In our view, Valens is a Canadian leader in services relating to cannabis extraction, purification, formulation and manufacturing. As the company leverages this platform to ramp up sales domestically and abroad, we believe 2020 will be a breakout year," analysts Kimberly Hedlin and Alisa Nagorny wrote.


Co-Diagnostics Inc (NASDAQ:CODX), a molecular diagnostics company, said that it has struck definitive agreements with institutional investors for buying 3,448,278 shares at a purchase price per share of \$1.45 in a registered direct offering priced at-the-market. The Salt Lake City, Utah-based company said the closing of the offering is expected on, or about January 28, and it will use the \$5 million in proceeds to expand its infectious disease testing, and vector control verticals.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) revealed Friday that it had successfully completed the required fed-fasting and dose proportionality tests of its lead product candidate, Tonmya, or TNX-102 SL, in healthy volunteers to support the new drug applications for the drug in treating post-traumatic stress disorder (PTSD) and fibromyalgia. In a statement, the New York-based clinical-stage biopharmaceutical company said the preliminary results of the study

**Price:** 0.6056

**Market Cap:** \$33.03 m

### 1 Year Share Price Graph



### Share Information

**Code:** TNXP

**Listing:** NASDAQ

52 week	High	Low
	12.6	0.276

**Sector:** Pharma & Biotech

**Website:** [www.tonixpharma.com](http://www.tonixpharma.com)

### Company Synopsis:

*Tonix is a clinical-stage biopharmaceutical company focused on discovering and developing small molecules and biologics to treat psychiatric, pain and addiction conditions. Tonix's lead product candidate, TNX-102 SL\*, is in development for posttraumatic stress disorder (PTSD), fibromyalgia, agitation in Alzheimer's disease (AAD) and alcohol use disorder (AUD).*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

showed "no significant effect" of a fatty meal on the rate or extent of absorption of TNX-102 SL 5.6 mg administered as 2 x 2.8 mg sublingual tablets.

Metalla Royalty & Streaming Ltd (CVE:MTA) (OTCMKTS:MTAFF), the precious metals streaming firm, is eyeing cash flow from two of its Argentinian assets beginning in the first calendar quarter of 2020. Reporting results for its fiscal second quarter on Friday to end-November last year, the firm said Pan American Silver (NASDAQ:PAAS) had made 'significant' progress in the period at the COSE and Joaquin mines, where it holds a 1.5% and 2% net smelter royalty respectively.

1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF), the cannabis-brand focused group, announced a raft of board changes on Friday, including two new senior executives and a new chairman. Terry Taouss becomes the new chair, while two seasoned senior executives in the beauty and CPG (consumer packaged goods) industries respectively Lisa Capparelli and Mark Baynes have joined as directors. Brayden Sutton and Cameron Watt have resigned as directors, the former to focus on his family, the company said in a statement.

CleanSpark Inc (NASDAQ:CLSK) announced Friday it has won a \$142,000 contract to provide software controls and energy storage to support a retail facility in California. In a statement, the company said it will integrate a scalable 43 kilowatt DC (direct current) solar array, 60kW/120kWh battery energy storage system from EnerPort Inc, and a 150-200kW generator, all driven by CleanSpark's mPulse software and controls platform.

Pressure BioSciences Inc (OTCMKTS:PBIO) announced a purchase order for six of its CBD oil-processing Ultra Shear Technology nanoemulsification systems. Jason Ellis, president of Vegas CBD Factory, placed the order for six BaroShear K45 systems.

GlobeX Data Ltd (CSE:SWIS) (OTCMKTS:SWISF) said it received "a lot of interest" from investors about the firm's cybersecurity platforms at a recent conference in the Bahamas. The New York- and Toronto-based company was at the AlphaNorth 2020 Capital Conference last week in Nassau, where it conducted over a dozen one-on-one meeting with investors and advisors from Canada, the US and Europe. "The AlphaNorth 2020 Capital Conference offered us an opportunity to tell our story to the investment community," CEO Alain Ghiai told shareholders.

DXI Energy Inc. (TSX:DXI) (OTCMKTS:DXIEF), an upstream oil and natural gas exploration and production company operating projects in Colorado's Piceance Basin and the Peace River Arch region in British Columbia announced that it has issued 2,215,068 shares to each of Hodgkinson Equities Corporation and Hodgkinson Ventures Inc., for a total of 4,430,136 shares following receipt of all final private placement approvals from the appropriate Canadian regulatory authorities. HEC and HVI are the company's secured lenders and the issuance of the shares is in lieu of cash payment of interest owing on the \$4,000,000 in secured loans of \$132,904.08 for the period from May 1, 2019 to December 31, 2019.

Tinka Resources Limited (CVE:TK) (OTCMKTS:TKRFF) said it has granted stock options to certain directors, officers and consultants to purchase an aggregate of 6,450,000 common shares in the company at an exercise price of \$0.25 per optioned share for a period of five years.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Tonix Pharmaceuticals named herein, including the promotion by the Company of Tonix Pharmaceuticals in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).